Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation that produces the BCR-ABL fusion oncogene which is detectable in over 90% of patients at presentation. The BCR-ABL inhibitor imatinib mesylate (IM) has improved survival in all phases of CML and is the standard of c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Swords, Ronan, Mahalingam, Devalingam, Padmanabhan, Swaminathan, Carew, Jennifer, Giles, Francis
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2009
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2769239/
https://ncbi.nlm.nih.gov/pubmed/19920925
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller